maplirpacept + tafasitamab + lenalidomide

This drug is a **combination therapy of maplirpacept (PF-07901801), tafasitamab, and lenalidomide** under investigation for the treatment of **relapsed or refractory diffuse large B-cell lymphoma (DLBCL)**, a type of non-Hodgkin lymphoma. - **Maplirpacept (PF-07901801)** is an anti-CD47 molecule that blocks the CD47-mediated "don't eat me" signal on tumor cells, thereby enhancing phagocytosis and the antitumor activity of macrophages. - **Tafasitamab** is a monoclonal antibody targeting CD19 on B cells, inducing antibody-dependent cellular cytotoxicity and phagocytosis. - **Lenalidomide** is an immunomodulatory small molecule that has direct anti-tumor effects, enhances immune cell function, and can augment the activity of antibodies like tafasitamab. This specific combination is being tested in adults with DLBCL who are not eligible for, or unwilling or unable to receive, autologous stem cell transplantation or CAR-T cell therapy. The trial is open-label, multicenter, and in Phase 1b/2, primarily evaluating safety, tolerability, and preliminary efficacy of the combination along with dose-finding for maplirpacept[1][2][4].